Patents by Inventor Tilak K. Sundaresan

Tilak K. Sundaresan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LNA-based mutant enrichment next-generation sequencing assays
    Patent number: 10876151
    Abstract: Ultra-sensitive assays for the detection of mutations, e.g., from blood-based sources of tumor genetic material (circulating tumor cells or plasma), or other settings in which limiting amounts of DNA, e.g., tumor DNA, is available. The assay is exemplified in the estrogen receptor, but is broadly customizable to target mutations in other genes.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: December 29, 2020
    Assignee: The General Hospital Corporation
    Inventors: Tilak K. Sundaresan, Zongli Zheng, Daniel A. Haber, Shyamala Maheswaran, A. John Iafrate
  • LNA-Based Mutant Enrichment Next-Generation Sequencing Assays
    Publication number: 20180112259
    Abstract: Ultra-sensitive assays for the detection of mutations, e.g., from blood-based sources of tumor genetic material (circulating tumor cells or plasma), or other settings in which limiting amounts of DNA, e.g., tumor DNA, is available. The assay is exemplified in the estrogen receptor, but is broadly customizable to target mutations in other genes.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 26, 2018
    Inventors: Tilak K. Sundaresan, Zongli Zheng, Daniel A. Haber, Shyamala Maheswaran, A. John Iafrate